Investing
Genentech (DNA) Will Regret Turning Roche Down
Published:
Last Updated:
The board of Genentech (DNA) turned down an $86.50 offer by Roche to buy the part of the company that it does not already own.
Until about a month ago, the offer had been higher–$89.
The board is making a huge mistake and it is likely to cost shareholders a bundle. After the first offer was made last July, DNA shares moved above $90. They stayed there through the summer. As doubts emerged about the Roche offer, the stock moved back down to $85, which is where it trades today.
What the Genentech board is avoiding is the fact that its stock has not been consistently above $90 since 2005.
Genentech asked Roche for $112 a share. It is not dealing from a position of strength. There are not likely to be other buyers during an economic downturn.
When Genentech announced earnings for its last quarter and issued its 2009 forecast, both were below Wall St. expectations. If it walks way from the Roche deal, its shares will drop back to where they were when the whole matter started–$75.
Douglas A. McIntyre
It’s Your Money, Your Future—Own It (sponsor)
Retirement can be daunting, but it doesn’t need to be.
Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!
Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.